Inhibition of Advanced Glycation and Absence of Galectin‐3 Prevent Blood‐Retinal Barrier Dysfunction during Short‐Term Diabetes
Open Access
- 1 January 2007
- journal article
- research article
- Published by Wiley in Journal of Diabetes Research
- Vol. 2007 (1) , 51837
Abstract
Breakdown of the inner blood‐retinal barrier (iBRB) occurs early in diabetes and is central to the development of sight‐threatening diabetic macular edema (DME) as retinopathy progresses. In the current study, we examined how advanced glycation end products (AGEs) forming early in diabetes could modulate vasopermeability factor expression in the diabetic retina and alter inter‐endothelial cell tight junction (TJ) integrity leading to iBRB dysfunction. We also investigated the potential for an AGE inhibitor to prevent this acute pathology and examined a role of the AGE‐binding protein galectin‐3 (Gal‐3) in AGE‐mediated cell retinal pathophysiology. Diabetes was induced in C57/BL6 wild‐type (WT) mice and in Gal‐3−/− transgenic mice. Blood glucose was monitored and AGE levels were quantified by ELISA and immunohistochemistry. The diabetic groups were subdivided, and one group was treated with the AGE‐inhibitor pyridoxamine (PM) while separate groups of WT and Gal‐3−/− mice were maintained as nondiabetic controls. iBRB integrity was assessed by Evans blue assay alongside visualisation of TJ protein complexes via occludin‐1 immunolocalization in retinal flat mounts. Retinal expression levels of the vasopermeability factor VEGF were quantified using real‐time RT‐PCR and ELISA. WT diabetic mice showed significant AGE ‐immunoreactivity in the retinal microvasculature and also showed significant iBRB breakdown (P < .005). These diabetics had higher VEGF mRNA and protein expression in comparison to controls (P < .01). PM‐treated diabetics had normal iBRB function and significantly reduced diabetes‐mediated VEGF expression. Diabetic retinal vessels showed disrupted TJ integrity when compared to controls, while PM‐treated diabetics demonstrated near‐normal configuration. Gal‐3−/− mice showed significantly less diabetes‐mediated iBRB dysfunction, junctional disruption, and VEGF expression changes than their WT counterparts. The data suggests an AGE‐mediated disruption of iBRB via upregulation of VEGF in the diabetic retina, possibly modulating disruption of TJ integrity, even after acute diabetes. Prevention of AGE formation or genetic deletion of Gal‐3 can effectively prevent these acute diabetic retinopathy changes.Keywords
Funding Information
- Wellcome
- Juvenile Diabetes Research Foundation Australia
This publication has 59 references indexed in Scilit:
- RETRACTED: Methylglyoxal Modification of mSin3A Links Glycolysis to Angiopoietin-2 TranscriptionCell, 2006
- Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endotheliumExperimental Eye Research, 2005
- Dynamic contrast enhanced MRI in patients with diabetic macular edema: initial resultsExperimental Eye Research, 2005
- Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic ratsBiochemical Society Transactions, 2003
- The Role of Advanced Glycation End Products in Retinal Microvascular LeukostasisInvestigative Ophthalmology & Visual Science, 2003
- Maillard reaction products in tissue proteins: New products and new perspectivesAmino Acids, 2003
- Inhibition of advanced glycation end‐products protects against retinal capillary basement membrane expansion during long‐term diabetesThe Journal of Pathology, 2003
- The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese ratsKidney International, 2003
- Nonsteroidal anti‐inflammatory drugs prevent early diabetic retinopathy via TNF‐α suppressionThe FASEB Journal, 2002
- The Role of Galectin-3 in Endocytosis of Advanced Glycation End Products and Modified Low Density LipoproteinsBiochemical and Biophysical Research Communications, 2001